<DOC>
	<DOCNO>NCT00497172</DOCNO>
	<brief_summary>The main objective study assess safety effectiveness Sirolimus-eluting stent CYPHERTM and/or update version reduce angiographic in-stent late loss de novo native coronary lesion diabetic patient compare bare metal Bx SONIC balloon-expandable stent . The secondary objective ass cost-effectiveness express incremental cost/life year gain cost/quality adjust life year gain different time point ( 8 month , 1 year ) .</brief_summary>
	<brief_title>Diabetes Drug Eluting Sirolimus Stent Experience Restenosis Trial</brief_title>
	<detailed_description>This multicenter ( 11 center ) , prospective , randomized single blind study . This study 2-arm design assess safety effectiveness Sirolimus-eluting stent CYPHERTM and/or update version bare metal Bx SONICTM stent . A total 250 patient enter study randomize 1:1 basis . Patients meet eligibility criterion either randomize Sirolimus-eluting stent bare metal Bx SONIC stent . The investigator blind out appearance system implant Sirolimus-eluting stent differs bare metal stent therefore immediately recognize surgeon . However patient know stent implant . Patients follow 30 day , 9 12 month post-procedure , patient undergo repeat angiography 8 month . Additionally , medical cost associate index hospitalization length stay , repeat hospitalization cost associate relevant medical resource use 1 year follow-up period collect analyzed .</detailed_description>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<criteria>1 . The patient must ≥ 18 year age ; 2 . Female childbearing potential must negative pregnancy test within 7days enrollment utilize reliable birth control eight month enrollment ; 3 . Patients IDDM ( Type I ) treat least 3 month document HbA1c , NIDDM ( Type II ) treat oral antidiabetic least 3 month ; 4 . Diagnosis angina pectoris define Canadian Cardiovascular Society Classification ( CCS I , II , III , IV ) OR unstable angina pectoris ( Braunwald Classification B &amp; C , III ) OR patient document silent ischemia OR patient previous ( &gt; 24 hour ) myocardial infarction document residual ischemia and/or viable myocardium ; 5 . Single double stent treatment de novo lesion major coronary artery patient single multivessel disease ; patient multivessel disease include maximum two vessel require treatment maximum three lesion total , two lesion per vessel . The two lesion single vessel must &gt; 10 mm apart ( visual estimate ) must treat assigned stent . 6 . Target vessel diameter lesion site ≥ 2.50mm ≤ 3.5mm diameter ( visual estimate ) ; 7 . Target lesion ≥ 13mm ≤ 25mm length ( visual estimate ) ; 8 . Target lesion stenosis &gt; 50 % &lt; 100 % ( visual estimate ) ; 9 . At least TIMI II coronary flow ; 10 . Acceptable candidate coronary artery bypass surgery ( CABG ) ; 11 . Patient willing comply specify followup evaluation ; 12 . Patient must provide write informed consent prior procedure use form approve local Ethics Committee ; 13 . Patient pretreated aspirin clopidogrel , alternatively , aspirin alone plus load dose 300 mg clopidogrel procedure completion case urgent PCI , GPIIb IIIa inhibitor ( Tirofiban Abciximab ) 1 . Patient experience Qwave nonQwave myocardial infarction document total CK &gt; 2 time normal within precede 24 hour CK CKMB enzymes remain normal time treatment ; 2 . Unprotected leave main coronary disease ≥50 % stenosis ; 3 . Significant ( &gt; 50 % ) stenoses proximal distal target lesion might require revascularization impede runoff ; 4 . Have target lesion arterial venous bypass graft ; 5 . Calcified lesion successfully predilated ; 6 . Documented leave ventricular ejection fraction ≤ 30 % ; 7 . TIMI 0I coronary flow ; 8 . Impaired renal function ( creatinine &gt; 3.0 mg/dl ) time treatment ; 9 . Pretreatment device balloon angioplasty ; 10 . Target lesion excessive tortuousity angulation ( &gt; 45° ) make unsuitable stent delivery deployment ; 11 . Target lesion involve bifurcation include diseased side branch ≥2 mm diameter ( either stenosis main vessel major branch stenosis major branch ) would require side branch stenting ; 12 . Prior stent within 5mm target lesion ; 13 . Direct Stenting ; 14 . Recipient heart transplant ; 15 . Patient life expectancy le 12 month ; 16 . Known allergy follow : aspirin , clopidogrel bisulfate ( Plavix ) , heparin GPIIb IIIa inhibitor ( Tirofiban Abciximab ) stainless steel , contrast agent ( manage medically ) , sirolimus ; 17 . Recent ( 6 month ) cerebrovascular accident intracranial hemorrhage ; 18 . Any significant medical condition investigator.s opinion may interfere patient.s optimal participation study ; 19 . Currently participate investigational drug another device study ; 20 . Intervention another lesion occur within 6 month index procedure ; 21 . In investigator.s opinion , lesion suitable stenting .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2010</verification_date>
</DOC>